Attention! The hundreds-of-billions-yuan analgesic market is witnessing a "non-opioid" revolution.

01 product Introduction

Suzetrigine (brand name: JOURNAVX®, CAS: 2649467-58-1) is an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor indicated for the treatment of adults with moderate to severe acute pain.

The chemical structure is:

4-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamido)picolinamide。

02The "non-opioid" blockbuster that is rewriting the history of pain management

A voltage-gated sodium channel 1.8 (Nav1.8) blocker developed by Vertex Pharmaceuticals of the United States was approved for marketing by the U.S. FDA on January 30,2025. As the world's first marketed selective Nav1.8 inhibitor, it represents not only the first novel mechanism-of-action non-opioid oral analgesic in over two decades but also breaks the century-long monopoly of opioid-based therapies in the treatment of moderate to severe pain, offering a new option for hundreds of millions of patients worldwide with pain who seek "highly effective pain relief without the risk of addiction."

Key Highlights

Suzetrigine blocks pain signals by selectively inhibiting the NaV1.8 sodium channel in peripheral pain neurons without acting on the central nervous system; consequently, it exhibits no addictive potential and no respiratory depression, making it a revolutionary alternative to opioid-based analgesics. Leveraging this unique advantage, its projected global peak sales are estimated at $2.9–$3 billion.

Market Prospects: In the United States, approximately 80 million patients receive pharmacological treatment for moderate to severe acute pain annually, among whom about 40 million are prescribed opioid medications. Suzetrigine is expected to gradually replace opioids, offering an exceptionally vast market potential.

03 Patent Analysis: The protection period remains relatively long, but now is the ideal time for patent strategy deployment.

analysis：The patent protection period for Suzetrigine compounds is relatively long (until 2040), meaning generic drugs cannot be directly launched in the short term. However, starting now to strategically invest in impurity research and process development represents the optimal window for building a strategic reserve for the future. Of particular note is chiral control—since the molecule contains four chiral centers, the originator company achieved a single enantiomer by employing SFC-based preparation and purification; this not only constitutes a technical barrier but also serves as our entry point for service provision.

04 Impurity profile analysis: Chiral control is the core challenge

The structure of Suzetrigine is highly complex, containing four chiral centers, amide bonds, pyridine rings, and sensitive functional groups such as trifluoromethyl groups; therefore, impurity control represents the greatest challenge in generic drug development. Based on the original research process patents (e.g., CN114945566B) and literature reports, four major categories of key impurities have been identified.

01 Chiral isomers (core challenge)

The molecule contains 4 chiral centers, making it prone to the formation of diastereomers and enantiomers during synthesis. In the original manufacturing process, a single configuration is obtained through SFC-based purification.

focus point：Development of chiral separation methods (SFC or chiral HPLC), chiral reference standards, and chiral control strategies in the manufacturing process

02 Process-related impurities (introduced from the starting materials and by-products)

Typical impurities：Suzetrigine Impurity 1 (CAS: 2649470-87-9) is a tetrahydrofuran ring carboxylic acid derivative derived from hydrolysis reactions or residual carboxylic acid intermediates.

focus point：Using Suzetrigine impurity 1 (CAS: 2649469-27-0) as the starting material allows for the fixation of two chiral centers, thereby reducing the complexity of the synthesis process.

03 API degradation impurities

04 Potential genotoxic impurities

05 What can we do for you? Suzetrigine's one-stop custom synthesis service

We boast a synthetic team led by a PhD researcher, an independent preparation department, and a complete suite of analytical instruments (including 400 MHz NMR, LC-MS, preparative HPLC, SFC, etc.), to provide you with comprehensive support.

✅ High-purity impurity reference standard (purity ≥ 95%; provides COA, MS, NMR, and HPLC spectra).

✅ Intermediate and API Process Development

✅ Custom Synthesis Services

Why choose us?

✓Professional Team

Combines a PhD and Master's degree, with extensive experience in pharmaceutical companies and CROs.

✓Equipped with complete facilities

Equipped with in-house MRI, mass spectrometry, and preparative liquid chromatography capabilities; no external collaborations required.

✓price advantage

Similar products are cheaper than others.

✓successful case

Has provided impurity reference standards to multiple generic drug manufacturers.

06 jump into action

The patent for Suzetrigine compounds expires in 2040; although the protection period is long, the complexity of chiral impurities dictates exceptionally high research barriers and an extremely lengthy research cycle. Now is the ideal time to proactively establish a framework for impurity studies and the development of chiral methodologies—we welcome your inquiry.

Click the official website to view the full QCS's Suzetrigine standard product series

QCS has obtained ANAB ISO 17034 accreditation; its reference material production and calibration processes comply with the international requirements for the accreditation of reference material producers, enabling QCS to provide data support for regulatory submissions to authorities such as the NMPA, EMA, and FDA that is internationally recognized.